ClinicalTrials.gg
Active, not recruitingNCT06049212TroFuse-008Updated Sep 2, 2026

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

A Phase 1 interventional study of Sacituzumab tirumotecan and Pembrolizumab in Non-small Cell Lung Cancer, Solid Tumors and Programmed Cell Death-1 (PD1, PD-1), sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 7 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 26 under way, 9 of them phase 3. sacituzumab tirumotecan · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
22nd of 26
30 · median 115
Started
2023
with 4 others
Phase 1
Only one
of the 26
Primary completion
2027-12
later than 14 of 25 live
Registered
5th of 26
by date
Lead sponsor
6 of 26
Merck Sharp & Dohme LLC

Among the 26 studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung, this one is the 22nd largest by planned enrollment, is one of 5 that started in 2023, is the only one in phase 1, reaches primary completion later than 14 of the 25 other live ones, and was the 5th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 26 studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About sacituzumab tirumotecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a phase 1 trial of the safety, tolerability, and pharmacokinetics (PK) of sacituzumab tirumotecan monotherapy, and of sacituzumab tirumotecan in combination with pembrolizumab (MK-3475) or pembrolizumab + carboplatin, in Japanese participants with advanced solid tumors or treatment-naïve advanced or metastatic non-small cell lung cancer (NSCLC).

Per protocol amendment 04, Arm 3: Pembrolizumab/Carboplatin + sacituzumab tirumotecan Combination Therapy was discontinued, and subsequently all Arm 3 procedures, recruitment, and descriptions were removed.

03

Conditions studied

  • Non-small Cell Lung Cancer
  • Solid Tumors
  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
  • Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Arm 1: or cytologically confirmed advanced/ solid tumor by pathology report and have received, or been intolerant to, all treatment known to confer clinical benefit.
  • Arm 2: Have a histologically or cytologically confirmed diagnosis of advanced or metastatic NSCLC (Stage IIIB or IIIC disease and not candidates for surgical resection or definitive chemoradiation, or Stage IV NSCLC, AJCC Staging Manual, version 8).
  • Arm 2: Confirmation that EGFR-, ALK-, or ROS1-directed therapy is not indicated as primary therapy
  • Arm 2: Has tumor tissue that demonstrates TPS ≥ 50% as determined by PD-L1 IHC 22C3 pharmDx assay by local laboratory
  • If capable of producing sperm, the participant agrees to the following during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention (100 days for sacituzumab tirumotecan and 90 days for carboplatin [no restriction for pembrolizumab]) AND agrees to refrain from donating sperm AND is either abstinent and agrees to remain abstinent or uses highly effective
  • For females (assigned at birth), is not pregnant or breastfeeding and ≥1 of the following applies: is not a participant of (POCBP) OR is a POCBP and uses highly effective contraception
  • Arm 1: Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline
  • by 1.1 as assessed by the local site investigator/radiology
  • sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated has been provided
  • Have a of at least 3 months
  • Have an performance status of 0 or 1 within 3 days before the start of study intervention

Exclusion criteria

Exclusion Criteria:

  • Has symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible
  • Has Grade ≥2 peripheral neuropathy
  • Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
  • Has active inflammatory bowel disease requiring medication or previous history of inflammatory bowel disease
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease including Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of interval to >480 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention
  • Received prior treatment with a TROP2-targeted ADC
  • Received prior treatment with a topoisomerase I-containing ADC
  • Arm 1: Has received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher irAE (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis
  • Arm 2: Received prior therapy with an , anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137)
  • Arm 2: Has received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their advanced or NSCLC
  • Arm 2: Has received radiation therapy to the lung that is >30 Gy within 6 months of the first dose of study intervention
  • Received prior systemic anticancer therapy including agents within 4 weeks before allocation
  • Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring
  • Received a live or within 30 days before the first dose of study intervention
  • Requires treatment with a strong inhibitor or inducer of at least 14 days before the first dose of study intervention and throughout the study
  • Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration
  • Arm 2: Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication
  • Arm 2: Active disease that has required systemic treatment in the past 2 years except replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid)
  • Known additional that is progressing or has required active treatment within the past 3 years
  • Known active and/or carcinomatous meningitis
  • History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Active infection requiring systemic therapy
  • History of infection
  • Concurrent active (defined as HBsAg positive and/or detectable HBV DNA) and virus (defined as anti-HCV Ab positive and detectable HCV RNA) infection
  • History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator
  • Known psychiatric or substance abuse disorder
  • A severe reaction to treatment a monoclonal antibody/component of the study intervention
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Arm 1: Sacituzumab tirumotecan Monotherapy

    Participants receive single doses of sacituzumab tirumotecan monotherapy once every 2 weeks (Q2W).

    Biological: Sacituzumab tirumotecan · Drug: Supportive care measures

  • Experimental
    Arm 2: Pembrolizumab + Sacituzumab tirumotecan Combination Therapy

    Participants receive sacituzumab tirumotecan Q2W in combination with pembrolizumab once every 6 weeks (Q6W).

    Biological: Sacituzumab tirumotecan · Biological: Pembrolizumab · Drug: Supportive care measures

Interventions

  • Sacituzumab tirumotecan injection powder for intravenous (IV) infusion.

    Also known as: SKB264, MK-2870

  • BiologicalPembrolizumab

    Pembrolizumab solution for IV infusion.

    Also known as: MK-3475

  • DrugSupportive care measures

    Participants are allowed to take supportive care measures at the discretion of the investigator. Prophylactic supportive care measures may include but are not limited to antiemetic agents, antidiarrheal agents, granulocyte and erythroid growth factors, and blood transfusions

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Dose-Limiting Toxicity (DLT)

    A DLT is defined as any of the following: Grade 4 nonhematologic toxicity; Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia or lymphopenia; any nonhematologic AE ≥Grade 3 in severity (with some exceptions); any Grade 3 or Grade 4 nonhematologic laboratory value (if certain criteria are met); febrile neutropenia Grade 3 or Grade 4; a prolonged delay (\>2 weeks) in initiating sacituzumab tirumotecan second dose due to intervention-related toxicity; any intervention-related toxicity that causes the participant to discontinue intervention during DLT evaluation period; or any Grade 5 toxicity. All toxicities will be graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.

    Time frame: Up to 21 days after each dose

  2. Number of Participants Experiencing ≥1 Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to ~32 months

  3. Number of Participants Discontinuing from Study Therapy due to AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to ~32 months

Secondary outcomes

  1. Area Under the Plasma Concentration-Time Curve (AUC) of sacituzumab tirumotecan -Antibody-Drug Conjugate (sacituzumab tirumotecan ADC)

    The AUC of sacituzumab tirumotecan -ADC will be determined in participants from Arm 1.

    Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion

  2. Maximum Plasma Concentration (Cmax) of sacituzumab tirumotecan-ADC

    The Cmax of sacituzumab tirumotecan-ADC will be determined in participants from Arm 1.

    Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion

  3. Minimum Plasma Concentration (Cmin) of sacituzumab tirumotecan-ADC

    The Cmin of sacituzumab tirumotecan-ADC will be determined in participants from Arm 1.

    Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion

  4. Apparent terminal half-life (t½) of sacituzumab tirumotecan-ADC

    The t½ of sacituzumab tirumotecan-ADC will be determined in participants from Arm 1.

    Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion

  5. Time to Maximum Plasma Concentration (Tmax) of sacituzumab tirumotecan-ADC

    The Tmax of sacituzumab tirumotecan-ADC will be determined in participants from Arm 1.

    Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion

  6. Clearance (CL) of sacituzumab tirumotecan-ADC

    The CL of sacituzumab tirumotecan-ADC will be determined in participants from Arm 1.

    Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion

  7. Volume of Distribution (Vz) of sacituzumab tirumotecan-ADC

    The Vz of sacituzumab tirumotecan-ADC will be determined in participants from Arm 1.

    Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion

  8. Accumulation Ratio (Rac) of sacituzumab tirumotecan-ADC

    The Rac of sacituzumab tirumotecan-ADC will be determined in participants from Arm 1.

    Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion

  9. Area Under the Plasma AUC of sacituzumab tirumotecan-Total Antibody (sacituzumab tirumotecan-TAB)

    The AUC of sacituzumab tirumotecan-TAB will be determined in participants from Arm 1.

    Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion

  10. Cmax of sacituzumab tirumotecan-TAB

    The Cmax of sacituzumab tirumotecan-TAB will be determined in participants from Arm 1.

    Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion

  11. Cmin of sacituzumab tirumotecan-TAB

    The Cmin of sacituzumab tirumotecan-TAB will be determined in participants from Arm 1.

    Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion

  12. t½ of sacituzumab tirumotecan-TAB

    The t½ of sacituzumab tirumotecan-TAB will be determined in participants from Arm 1.

    Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion

  13. Tmax of sacituzumab tirumotecan-TAB

    The Tmax of sacituzumab tirumotecan-TAB will be determined in participants from Arm 1.

    Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion

  14. CL of sacituzumab tirumotecan-TAB

    The CL of sacituzumab tirumotecan-TAB will be determined in participants from Arm 1.

    Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion

  15. Vz of sacituzumab tirumotecan-TAB

    The Vz of sacituzumab tirumotecan-TAB will be determined in participants from Arm 1.

    Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion

  16. Rac of sacituzumab tirumotecan-TAB

    The Rac of sacituzumab tirumotecan-TAB will be determined in participants from Arm 1.

    Time frame: Day 1: Preinfusion and 0.5, 2, 4, 8, 24, 48, and 72 hours postinfusion

  17. Cmax of sacituzumab tirumotecan-ADC Coadministered with Pembrolizumab

    The Cmax of sacituzumab tirumotecan-ADC when coadministered with pembrolizumab will be determined in participants from Arm 2.

    Time frame: Cycle 1 and 2: Days 1 and 29 preinfusion and 0.5 hours postinfusion (each cycle is 29 days)

  18. Cmin of sacituzumab tirumotecan-ADC Coadministered with Pembrolizumab

    The Cmin of sacituzumab tirumotecan-ADC when coadministered with pembrolizumab will be determined in participants from Arm 2.

    Time frame: Cycle 1 and 2: Days 1 and 29 preinfusion and 0.5 hours postinfusion (each cycle is 29 days)

  19. Rac of sacituzumab tirumotecan-ADC Coadministered with Pembrolizumab

    The Rac of sacituzumab tirumotecan-ADC when coadministered with pembrolizumab will be determined in participants from Arm 2.

    Time frame: Cycle 1 and 2: Days 1 and 29 preinfusion and 0.5 hours postinfusion (each cycle is 29 days)

  20. Cmax of sacituzumab tirumotecan-TAB Coadministered with Pembrolizumab

    The Cmax of sacituzumab tirumotecan-TAB when coadministered with pembrolizumab will be determined in participants from Arm 2.

    Time frame: Cycle 1 and 2: Days 1 and 29 preinfusion and 0.5 hours postinfusion (each cycle is 29 days)

  21. Cmin of sacituzumab tirumotecan-TAB Coadministered with Pembrolizumab

    The Cmin of sacituzumab tirumotecan-TAB when coadministered with pembrolizumab will be determined in participants from Arm 2.

    Time frame: Cycle 1 and 2: Days 1 and 29 preinfusion and 0.5 hours postinfusion (each cycle is 29 days)

  22. Rac of sacituzumab tirumotecan-TAB Coadministered with Pembrolizumab

    The Rac of sacituzumab tirumotecan-TAB when coadministered with pembrolizumab will be determined in participants from Arm 2.

    Time frame: Cycle 1 and 2: Days 1 and 29 preinfusion and 0.5 hours postinfusion (each cycle is 29 days)

  23. Cmax of KL610023 Coadministered with Pembrolizumab

    The Cmax of KL610023 (free payload) when sacituzumab tirumotecan is coadministered with pembrolizumab will be determined in participants from Arm 2.

    Time frame: Cycle 1 and 2: Days 1 and 29 preinfusion and 0.5 hours postinfusion (each cycle is 29 days)

  24. Rac of KL610023 Coadministered with Pembrolizumab

    The Rac of KL610023 (free payload) when sacituzumab tirumotecan is coadministered with pembrolizumab will be determined in participants from Arm 2.

    Time frame: Cycle 1 and 2: Days 1 and 29 preinfusion and 0.5 hours postinfusion (each cycle is 29 days)

  25. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

    Time frame: Up to ~39 months

  26. Duration of Response (DOR)

    DOR is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause.

    Time frame: Up to ~39 months

  27. Incidence of Antidrug Antibodies (ADA) to sacituzumab tirumotecan

    The incidence of ADA will be determined in participants from Arm 1 and Arm 2.

    Time frame: Up to ~32 months

  28. Incidence of Antidrug Antibodies (ADA) to pembrolizumab

    The incidence of ADA will be determined in participants from Arm 2.

    Time frame: Up to ~32 months

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2027, 50 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 50 months is close to that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2023
First posted
Sep 22, 2023
StartActual
Oct 26, 2023
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jan 29, 2028
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06049212
Responsible party
Sponsor
First posted
Sep 22, 2023
Start date
Oct 26, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Jan 29, 2028 (estimated)
Last update
Sep 2, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab tirumotecan

Start the discussion